Unrestricted Use of Drug-Eluting Stents Compared With Bare-Metal Stents in Routine Clinical PracticeFindings From the National Heart, Lung, and Blood Institute Dynamic Registry
J. Dawn Abbott, MD, FACC*,*,
Matthew R. Voss, MD*,
Mamoo Nakamura, MD ,
Howard A. Cohen, MD, FACC ,
Faith Selzer, PhD ,
Kevin E. Kip, PhD,
Helen A. Vlachos, MSc ,
Robert L. Wilensky, MD, FACC and
David O. Williams, MD, FACC*
* Department of Cardiology, Rhode Island Hospital, Providence, Rhode Island
Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
Lenox Hill Heart and Vascular Institute, New York, New York
Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Adjusted Kaplan-Meier Event Curves at 1 Year
Adjusted Kaplan-Meier event curves at 1 year for (A) freedom from death/myocardial infarction by stent type and (B) freedom from need for repeat revascularization rates by stent type.
|
|

View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Adjusted HRs and 95% CIs for 1 Year
Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for 1 year (A) death/myocardial infarction and (B) target vessel revascularization by percutaneous coronary intervention, according to lesion and stent types. BMS = bare-metal stent; DES = drug-eluting stent.
|
|
|